Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

FDA Advisory Hearing on New-Fill (Sculptra), March 25, 2004 in Gaithersburg, Maryland

February 27, 2004

On March 25, 2004 the FDA's General and Plastic Surgery Devices Panel will hold a public hearing on "a premarket approval application (PMA) for an injectable device intended for use in the correction of lipoatrophy of the face in HIV (human immunodeficiency virus) positive patients." AIDS Treatment News has learned that the application is for Sculptra, which is marketed in Europe under the name New-Fill. According to the Web site Drugs.com, it has been used by an estimated 100,000 people worldwide for various facial treatments.

Those who want to speak at the hearing should notify the FDA before March 15.

For more information on the logistics, visit www.fda.gov/cdrh/panel/index.html.

Click on "Upcoming CDRH Advisory Committee/Panel Meetings" then on "Details" for the March 25, 2004 meeting.

Advertisement
Also, background information on this application will be available to the public one day before the meeting, at www.fda.gov/cdrh/panelmtg.html.


ISSN # 1052-4207

Copyright 2004 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
 

Tools
 

Advertisement